Edge Wealth Management’s Scinai Immunotherapeutics SCNI Stock Holding History

Edge Wealth Management’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Hold	0	–	-$10K	–	443
2020 Q3	–	Hold	0	–	–	–	321
2019 Q2	–	Sell	-10	Closed	–	–	628
2019 Q1	$0	Buy	+10	New	+$52K	﹤0.01%	596
2018 Q1	–	Sell	-10	Closed	-$1K	–	575
2017 Q4	$1K	Hold	10	–	–	﹤0.01%	509
2017 Q3	$2K	Hold	10	–	–	﹤0.01%	492
2017 Q2	$2K	Hold	10	–	–	﹤0.01%	484
2017 Q1	$2K	Hold	10	–	–	﹤0.01%	460
2016 Q4	$1K	Buy	+10	New	+$36.3K	﹤0.01%	458

Other funds holding SCNI

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

NFG

Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

GRP

Global Retirement Partners San Rafael, California $6.54B AUM

Edge Wealth Management's SCNI Position: Q4 2020 in Review

Edge Wealth Management held its Scinai Immunotherapeutics (SCNI) position steady in Q4 2020 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #443.

Edge Wealth Management first reported a position in SCNI in Q4 2016 and has held it in 6 quarters since. The position peaked at $2K in Q3 2017. 10 funds tracked by Wall St. Rank hold SCNI as of Q4 2020.

Edge Wealth Management held 0 shares of Scinai Immunotherapeutics worth $0 as of Q4 2020.
Edge Wealth Management left its Scinai Immunotherapeutics share count unchanged in Q4 2020.
Scinai Immunotherapeutics made up ﹤0.01% of Edge Wealth Management's portfolio in Q4 2020, its #443 holding.
Edge Wealth Management first reported a position in Scinai Immunotherapeutics in Q4 2016 and has held it in 6 quarters since.
Edge Wealth Management's Scinai Immunotherapeutics position peaked at $2K in Q3 2017.
10 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q4 2020.

Based on Edge Wealth Management's 13F filing for Q4 2020, filed 19 Jan 2021.